safety and tolerability of revlimid and azacitidine combination 2 -3 years [clinicaltrials_resource:78bca83a6055c04cc913d85bf33a777c]
To determine the number of subjects who develop grade 4 toxicity while on combination therapy.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
safety and tolerability of revlimid and azacitidine combination 2 -3 years [clinicaltrials_resource:78bca83a6055c04cc913d85bf33a777c]
To determine the number of subjects who develop grade 4 toxicity while on combination therapy.
Bio2RDF identifier
78bca83a6055c04cc913d85bf33a777c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:78bca83a6055c04cc913d85bf33a777c
measure [clinicaltrials_vocabulary:measure]
safety and tolerability of revlimid and azacitidine combination
time frame [clinicaltrials_vocabulary:time-frame]
2 -3 years
description
To determine the number of sub ...... while on combination therapy.
identifier
clinicaltrials_resource:78bca83a6055c04cc913d85bf33a777c
title
safety and tolerability of revlimid and azacitidine combination 2 -3 years
@en
type
label
safety and tolerability of rev ...... ca83a6055c04cc913d85bf33a777c]
@en